MCID: MXD001
MIFTS: 18

Mixed Cerebral Palsy

Categories: Neuronal diseases

Aliases & Classifications for Mixed Cerebral Palsy

MalaCards integrated aliases for Mixed Cerebral Palsy:

Name: Mixed Cerebral Palsy 12 14
Cerebral Palsy, Mixed 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050673

Summaries for Mixed Cerebral Palsy

Disease Ontology : 12 A cerebral palsy that is caused by injury to both the pyramidal and extra pyramidal areas of the brain, which results in both the tight muscle tone and the involuntary movements. The individual have difficulty with speaking and swallowing.

MalaCards based summary : Mixed Cerebral Palsy, also known as cerebral palsy, mixed, is related to cerebral palsy and cerebritis. An important gene associated with Mixed Cerebral Palsy is LAX1 (Lymphocyte Transmembrane Adaptor 1). The drugs Dexmedetomidine and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and testes.

Related Diseases for Mixed Cerebral Palsy

Diseases related to Mixed Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 cerebral palsy 11.8
2 cerebritis 9.6

Symptoms & Phenotypes for Mixed Cerebral Palsy

Drugs & Therapeutics for Mixed Cerebral Palsy

Drugs for Mixed Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Levodopa Approved Phase 4 59-92-7 6047
5
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-84-3 187
6
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
7
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7487-88-9 24083
8
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
11
Inulin Approved, Nutraceutical Phase 4 9005-80-5 24763
12 Adrenergic Agents Phase 4,Phase 1
13 Adrenergic Agonists Phase 4,Phase 1
14 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
15 Adrenergic alpha-Agonists Phase 4,Phase 1
16 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
17 Analgesics, Non-Narcotic Phase 4,Phase 3
18 Anesthetics Phase 4,Phase 3,Phase 2
19 Anesthetics, General Phase 4
20 Anesthetics, Inhalation Phase 4
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
22 Hypnotics and Sedatives Phase 4
23 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Platelet Aggregation Inhibitors Phase 4
26 Autonomic Agents Phase 4,Phase 3,Phase 1
27 Carbidopa, levodopa drug combination Phase 4
28 Dihydroxyphenylalanine Phase 4
29 Dopamine Agents Phase 4
30 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
31 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1
32 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1
33 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1
34 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1
36 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1
37 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
38 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
39 calcium channel blockers Phase 4,Phase 3,Phase 2
40 Calcium, Dietary Phase 4,Phase 3,Phase 2
41 Tocolytic Agents Phase 4,Phase 3,Phase 2
42 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
43 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
44 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
45 Anesthetics, Local Phase 4
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
47 Anesthetics, Intravenous Phase 4
48 calcium heparin Phase 4
49 Acidophilus Nutraceutical Phase 4
50 Sunflower Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 575)

id Name Status NCT ID Phase Drugs
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
2 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
5 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
6 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
7 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
8 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
9 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
10 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies Completed NCT00964639 Phase 4 Ropivacaine;Saline
11 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
12 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
13 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
14 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4 magnesium
15 Post Marketing Surveillance Study of Dysport Completed NCT00210431 Phase 4
16 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
17 Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy Recruiting NCT02391324 Phase 4
18 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
19 Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation Recruiting NCT03117322 Phase 4
20 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
21 Intrathecal Baclofen (ITB) Delivery Location and Its Effect on Spasticity Recruiting NCT02903823 Phase 4 Baclofen bolus injection
22 Changes of Gas Values in Cord Blood Versus Time and Temperature Not yet recruiting NCT02785367 Phase 4
23 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
24 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
25 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years Unknown status NCT01832454 Phase 2, Phase 3
26 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
27 Targeted Hip Strength Training in Children With Cerebral Palsy (CP) Unknown status NCT01633736 Phase 3
28 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis Unknown status NCT01929434 Phase 3
29 Modulation of Brain Plasticity After Perinatal Stroke Unknown status NCT01189058 Phase 2, Phase 3
30 Magnesium Sulfate to Prevent Brain Injury in Premature Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
31 Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
32 Orthotics in Ambulatory Cerebral Palsy Completed NCT01527162 Phase 3
33 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy Completed NCT00261131 Phase 3 Botulinum Toxin A
34 The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial Completed NCT01437644 Phase 3 botulinum toxin intramuscular injection
35 Dutch National ITB Study in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
36 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy Completed NCT01893411 Phase 3 IncobotulinumtoxinA (16 Units per kg body weight);IncobotulinumtoxinA (12 Units per kg body weight);IncobotulinumtoxinA (4 Units per kg body weight)
37 Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy Completed NCT01905683 Phase 3 IncobotulinumtoxinA (16-20 Units per kg body weight)
38 Static and Dynamic Postural Stability in Cerebral Palsy Children Completed NCT01799304 Phase 3
39 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed NCT00491894 Phase 3 Oral Glycopyrrolate Liquid
40 A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years Completed NCT01898520 Phase 3 Sativex;Placebo
41 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
42 Dysport® Pediatric Lower Limb Spasticity Follow-on Study Completed NCT01251380 Phase 3 Botulinum type A toxin (Dysport®)
43 Dysport® Pediatric Lower Limb Spasticity Study Completed NCT01249417 Phase 3 Botulinum type A toxin (Dysport®);Placebo
44 Effects of Mirror Neurons Stimulation on Motor Skill Rehabilitation in Children With Cerebral Palsy Completed NCT01267929 Phase 3
45 Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) Completed NCT00014989 Phase 3 magnesium sulfate
46 Individualized Neurodevelopmental Treatment Completed NCT00922077 Phase 3
47 MEOPA to Improve Physical Therapy Results After Multilevel Surgery Completed NCT00632528 Phase 3 MEOPA;Medicinal air
48 BOTOX® Treatment in Pediatric Lower Limb Spasticity Completed NCT01603628 Phase 3 Normal Saline (Placebo)
49 BOTOX® Treatment in Pediatric Upper Limb Spasticity Completed NCT01603602 Phase 3 Normal Saline (Placebo)
50 Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Completed NCT00114543 Phase 3

Search NIH Clinical Center for Mixed Cerebral Palsy

Genetic Tests for Mixed Cerebral Palsy

Anatomical Context for Mixed Cerebral Palsy

MalaCards organs/tissues related to Mixed Cerebral Palsy:

39
Brain, Bone, Testes, Lung, Heart, Tongue, Spinal Cord

Publications for Mixed Cerebral Palsy

Articles related to Mixed Cerebral Palsy:

id Title Authors Year
1
Acoustic-phonetic contrasts and intelligibility in the dysarthria associated with mixed cerebral palsy. ( 1573870 )
1992

Variations for Mixed Cerebral Palsy

Expression for Mixed Cerebral Palsy

Search GEO for disease gene expression data for Mixed Cerebral Palsy.

Pathways for Mixed Cerebral Palsy

GO Terms for Mixed Cerebral Palsy

Sources for Mixed Cerebral Palsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....